Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors

NCT00492830 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Neoplasm Metastasis

Interventions

DRUG: TRC093 recombinant humanized IgG1k monoclonal antibody

Sponsor

Tracon Pharmaceuticals Inc.